|
Apr 1
|
Biotech stocks slide as Marks resignation seen being negative for sector
|
|
Feb 14
|
Galapagos NV (GLPG) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience
|
|
Feb 12
|
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
|
|
Feb 12
|
Galapagos NV (GLPG): A Cheap Biotech Stock to Invest In Now
|
|
Oct 7
|
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
|
|
May 16
|
Galapagos creates new subscription right plans
|
|
May 15
|
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
|
|
Apr 4
|
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
|
|
Apr 3
|
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
|
|
Feb 24
|
Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript
|
|
Feb 22
|
Galapagos announces full year 2023 results and outlook for 2024
|
|
Feb 22
|
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
|
|
Dec 19
|
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
|
|
Dec 9
|
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
|
|
Dec 7
|
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
|